Yarrow is developing a first-in-class antibody targeting TSHR for the treatment of Graves’ disease and thyroid eye disease.
Yarrow has raised $200.0M in total funding. The most recent round was Venture - Series Unknown. The last funding was announced in December 2025.
Yarrow's investors include Janus Henderson Investors, Perceptive Advisors, OrbiMed, RTW Investments, LifeSci Venture Partners.
Yarrow is headquartered in New York, United States.
Yarrow is developing a first-in-class antibody targeting TSHR for the treatment of Graves’ disease and thyroid eye disease.
Yarrow is at the Venture - Series Unknown stage.
Free to use in articles, research, and reference works. Stable URL — will not change. Data on this page last updated .
"Yarrow — Funding & Investors." VCBacked, December 17, 2025, https://www.vcbacked.co/company/yarrow. Accessed August 8, 2026.
VCBacked. (2025). Yarrow — Funding & Investors. Retrieved August 8, 2026, from https://www.vcbacked.co/company/yarrow
{{cite web |title=Yarrow — Funding & Investors |url=https://www.vcbacked.co/company/yarrow |website=VCBacked |access-date=August 8, 2026}}Profile data sourced and verified per the VCbacked methodology · Last funding round dated